# US 2019/0376086 A1 · Primary cell gene editing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376086 A1
- Document ID: US20190376086A1
- Status: Published application
- Kind: A1
- Application number: 16/552,786
- Filed: 2019-08-27
- Published: 2019-12-12
- Earliest claimed: 2017-10-30
- Assignees: Pact Pharma, Inc.
- Applicants: Pact Pharma, Inc.
- Inventors: KYLE JACOBY; ALEX FRANZUSOFF
- Web page: https://patentgrep.com/patent/US20190376086A1

## CPC

- C12N 15/90: Stable introduction of foreign DNA into chromosome
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/4201: {Neoantigens}
- A61K 40/4272: {Melan-A/MART}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/85: for animal cells
- C12N 15/907: {in mammalian cells}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2319/02: containing a signal sequence
- C07K 2319/50: containing protease site
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/315: Phosphorothioates
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2320/51: modulating the chemical stability, e.g. nuclease-resistance
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.

## Claims

### Claim at position 1

-332. (canceled)

### Claim 333

A polynucleotide comprising:
a. first and second homology arms homologous to first and second target nucleic acid sequences;
b. a TCR gene sequence positioned between the first and second homology arms; and
c. a first 2A-coding sequence positioned upstream of the TCR gene sequence and a second 2A-coding sequence positioned downstream of the TCR gene sequence, wherein the first and second 2A-coding sequences code for the same amino acid sequence but are codon-diverged relative to each other.

### Claim 334 (depends on 333)

The polynucleotide of claim 333, wherein the first and second homology arms are each from about 300 bases to about 2000 bases in length.

### Claim 335 (depends on 333)

The polynucleotide of claim 333, wherein the polynucleotide further comprises a second TCR gene sequence positioned between the second 2A-coding sequence and the second homology arm.

### Claim 336 (depends on 335)

The polynucleotide of claim 335, wherein the polynucleotide further comprises:
a. a first signal sequence positioned between the first 2A-coding sequence and the first TCR gene sequence;
b. a second signal sequence positioned between the second 2A-coding sequence and the second TCR gene sequence;
wherein the first and second signal sequences code for the same amino acid sequence but are codon-diverged relative to each other.

### Claim 337 (depends on 336)

The polynucleotide of claim 336, wherein the first, the second, or both 2A-coding sequences are immediately downstream of a sequence coding for the amino acid sequence Gly Ser Gly.

### Claim 338 (depends on 337)

The polynucleotide of claim 337, wherein a nucleic acid sequence coding for a Furin cleavage site is positioned between the TCR gene sequence the second 2A-coding sequence.

### Claim 339 (depends on 338)

The polynucleotide of claim 338, wherein the polynucleotide further comprises an exogenous sequence of interest.

### Claim 340 (depends on 339)

The polynucleotide of claim 339, wherein the exogenous sequence of interest codes for a protein useful in autologous cell therapy.

### Claim 341 (depends on 333)

The polynucleotide of claim 333, wherein the polynucleotide is a circular DNA molecule.

### Claim 342

A polypeptide comprising, in order from N-terminus to C-terminus:
a. a human growth hormone signal sequence;
b. a first 2A sequence;
c. a TCR polypeptide sequence; and
d. a second 2A sequence.

### Claim 343 (depends on 342)

The polypeptide of claim 342, wherein the first, the second, or both P2A sequences are immediately preceded by the amino acids Gly Ser Gly.

### Claim 344 (depends on 342)

The polypeptide of claim 342, wherein a Furin cleavage site is positioned between the TCR gene sequence the second P2A sequence.

### Claim 345

A method of treating cancer in a human patient comprising:
a. modifying a patient-derived T cell by introducing a polynucleotide into the T cell, wherein the polynucleotide comprises:
i. first and second homology arms homologous to first and second endogenous sequences of the cell;
ii. a TCR gene sequence positioned between the first and second homology arms; and
iii. a first 2A-coding sequence positioned upstream of the TCR gene sequence and a secondP2A-coding sequence positioned downstream of the TCR gene sequence, wherein the first and second 2A-coding sequences code for the same amino acid sequence but codon-diverged relative to each other;
b. recombining the polynucleotide into an endogenous locus of the T cell, wherein the endogenous locus comprises the first and second endogenous sequences homologous to the first and second homology arms of the polynucleotide; and
c. culturing the modified T cell to produce a population of T cells; and
d. administering a therapeutically effective number of the modified T cells to the human patient to thereby treat the cancer.

### Claim 346 (depends on 345)

The method of claim 345, wherein said recombining comprises:
a. cleavage of the endogenous locus by a nuclease; and
b. recombination of the polynucleotide into the endogenous locus by homology directed repair.

### Claim 347 (depends on 345)

The method of claim 345, wherein the polynucleotide further comprises a second TCR gene sequence positioned between the second 2A-coding sequence and the second homology arm.

### Claim 348 (depends on 345)

The method of claim 345, wherein the first and second homology arms are each from about 300 bases to about 2,000 bases in length.

### Claim 349 (depends on 345)

The method of claim 345, wherein the polynucleotide further comprises a human growth hormone signal sequence positioned between the first 2A-coding sequence and the TCR gene sequence.

### Claim 350 (depends on 345)

The method of claim 345, wherein a nucleic acid sequence coding for a Furin cleavage site is positioned between the TCR gene sequence the second 2A-coding sequence

### Claim 351 (depends on 345)

The method of claim 345, wherein prior to administering a therapeutically effective number of modified T cells, a non-myeloablative lymphodepletion regimen is administered to the subject.

### Claim 352 (depends on 345)

The method of claim 345, wherein the cancer is selected from the group consisting of melanoma, lung cancer, and colorectal cancer.
